Nippon Shinyaku and Taiho strike itching product alliance
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku has licensed an early-stage pipeline product for serious itching to Taihofor co-development and co-marketing in Japan. The compound, NS-141, is still at the preclinical stage and represents a new approach to serious itching related to disorders such as atopic dermatitis, Nippon Shinyaku said. Taiho will make undisclosed up front, milestone and royalty payments as part of the deal and will join the development programme from Phase I.